138 related articles for article (PubMed ID: 12594239)
1. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.
Diebold J; Seemüller F; Löhrs U
Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239
[TBL] [Abstract][Full Text] [Related]
2. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
3. K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
Alvarez AA; Moore WF; Robboy SJ; Bentley RC; Gumbs C; Futreal PA; Berchuck A
Gynecol Oncol; 2001 Feb; 80(2):201-6. PubMed ID: 11161860
[TBL] [Abstract][Full Text] [Related]
4. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
5. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
6. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
7. [K-ras mutation analysis in ovarian serous borderline and malignant tumors].
Ma L; Guo LN; Liang ZY; Ren XY; Wu SF
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253
[TBL] [Abstract][Full Text] [Related]
8. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
10. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
[TBL] [Abstract][Full Text] [Related]
11. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
13. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
16. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ
Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696
[TBL] [Abstract][Full Text] [Related]
18. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
19. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways.
Körner M; Burckhardt E; Mazzucchelli L
J Pathol; 2005 Sep; 207(1):20-6. PubMed ID: 16021676
[TBL] [Abstract][Full Text] [Related]
20. Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma.
McCluggage WG; Vosmikova H; Laco J
Int J Gynecol Pathol; 2020 Jan; 39(1):84-92. PubMed ID: 30575604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]